395 related articles for article (PubMed ID: 33964573)
1. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
[TBL] [Abstract][Full Text] [Related]
2. Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [
Xie HJ; Yu YF; Sun XS; Jia GD; Luo DH; Sun R; Liu LT; Guo SS; Liu SL; Chen QY; Tang LQ; Mai HQ
Cancer Med; 2020 Dec; 9(23):8852-8863. PubMed ID: 33034945
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA.
Liu LT; Chen QY; Tang LQ; Guo SS; Guo L; Mo HY; Li Y; Tang QN; Sun XS; Liang YJ; Zhao C; Guo X; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
J Natl Compr Canc Netw; 2019 Jun; 17(6):703-710. PubMed ID: 31200353
[TBL] [Abstract][Full Text] [Related]
4. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
5. Can Epstein-Barr virus-deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
Zhang Q; Peng ZW; Gu ZS; Wang Y; He F; Zhao WB; Luo W; Mei YY
Cancer Med; 2023 Jan; 12(1):223-235. PubMed ID: 35674137
[TBL] [Abstract][Full Text] [Related]
6. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
Lee VH; Kwong DL; Leung TW; Choi CW; O'Sullivan B; Lam KO; Lai V; Khong PL; Chan SK; Ng CY; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; So TH; Luk MY; Lee AW
Int J Cancer; 2019 Apr; 144(7):1713-1722. PubMed ID: 30192385
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma.
Li WZ; Wu HJ; Lv SH; Hu XF; Liang H; Liu GY; Lu N; Bei WX; Lv X; Guo X; Xia WX; Xiang YQ
JAMA Netw Open; 2021 Sep; 4(9):e2124721. PubMed ID: 34554238
[TBL] [Abstract][Full Text] [Related]
8. A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma.
Peng L; Chen YP; Xu C; Tang LL; Chen L; Lin AH; Liu X; Sun Y; Ma J
Oral Oncol; 2018 Nov; 86():258-265. PubMed ID: 30409310
[TBL] [Abstract][Full Text] [Related]
9. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
[TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
[TBL] [Abstract][Full Text] [Related]
11. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
[TBL] [Abstract][Full Text] [Related]
12. Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level.
Liu SL; Sun XS; Xie HJ; Chen QY; Lin HX; Liang H; Liang YJ; Li XY; Yan JJ; Lin C; Yang ZC; Guo SS; Liu LT; Tang QN; Du YY; Tang LQ; Guo L; Mai HQ
BMC Cancer; 2020 Feb; 20(1):89. PubMed ID: 32013967
[TBL] [Abstract][Full Text] [Related]
13. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
14. Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma.
Chen FP; Huang XD; Lv JW; Wen DW; Zhou GQ; Lin L; Kou J; Wu CF; Chen Y; Zheng ZQ; Li ZX; He XJ; Sun Y
Cancer; 2020 May; 126(10):2163-2173. PubMed ID: 32125701
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
16. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA.
Liang YJ; Wen DX; Luo MJ; Tang LQ; Guo SS; Wang P; Chen QY; Liu LT; Mai HQ
Eur J Cancer; 2021 Dec; 159():133-143. PubMed ID: 34743068
[TBL] [Abstract][Full Text] [Related]
17. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.
Leung SF; Chan KC; Ma BB; Hui EP; Mo F; Chow KC; Leung L; Chu KW; Zee B; Lo YM; Chan AT
Ann Oncol; 2014 Jun; 25(6):1204-8. PubMed ID: 24638904
[TBL] [Abstract][Full Text] [Related]
18. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.
Zhang J; Peng H; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
BMC Cancer; 2018 Dec; 18(1):1276. PubMed ID: 30567511
[TBL] [Abstract][Full Text] [Related]
19. The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma.
Liu LT; Tang LQ; Chen QY; Zhang L; Guo SS; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):862-9. PubMed ID: 26530755
[TBL] [Abstract][Full Text] [Related]
20. Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma.
Huang CL; Sun ZQ; Guo R; Liu X; Mao YP; Peng H; Tian L; Lin AH; Li L; Shao JY; Sun Y; Ma J; Tang LL
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):355-361. PubMed ID: 30682489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
